Versameb AG
The next generation of RNA therapeutics
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business team.
The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules in multiple disease areas with high unmet medical need including immunological disorders, oncology and myology.
For more information, please visit www.versameb.com.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
20.11.2023
FDA clearance spurs Versameb's clinical trial for mRNA drug against incontinence (startupticker.ch)
13.07.2023
Startups gather Board members’ expertise (startupticker.ch)
11.01.2021
New leaders on the executive floor (startupticker.ch)
16.07.2020
Versameb secures CHF 6 million in a seed round (startupticker.ch)
18.10.2019
Versameb raises CHF 6.4 million in Seed C financing round (startupticker.ch)
Last Tweets
No Jobs
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Versameb AG
The next generation of RNA therapeutics
Website:
www.versameb.com/
Headquarter:
Basel
Foundation Date:
August 2017
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Drug discovery
- Protein drugs
Support received
